Sorrentino; Jessica A.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Sorrentino; Jessica A..The latest application filed is for "treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors".

Company Profile

7.5.10

Sorrentino; Jessica A. - Durham NC

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors Grant 11,446,295 - Strum , et al. September 20, 2	2022-09-20
Treatment of EGFR-driven cancer with fewer side effects Grant 11,395,821 - Sorrentino , et al. July 26, 2	2022-07-26
Treatment Of Rb-negative Tumors Using Topoisomerase Inhibitors In Combination With Cyclin Dependent Kinase 4/6 Inhibitors App 20220175780 - Strum; Jay Copeland ; et al.	2022-06-09
Therapeutic Regimens For Treatment Of Cancer Using Eribulin And Selective Cdk4/6 Inhibitor Combinations App 20210267986 - Sorrentino; Jessica A. ; et al.	2021-09-02
Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors Grant 11,090,306 - Strum , et al. August 17, 2	2021-08-17
Treatment Of Cancers Having Driving Oncogenic Mutations App 20210030758 - Strum; Jay Copeland ; et al.	2021-02-04
Treatment Of Rb-negative Tumors Using Topoisomerase Inhibitors In Combination With Cyclin Dependent Kinase 4/6 Inhibitors App 20200022983 - Strum; Jay Copeland ; et al.	2020-01-23
Treatment Of Egfr-driven Cancer With Fewer Side Effects App 20190374545 - Sorrentino; Jessica A. ; et al.	2019-12-12
Preservation Of Immune Response During Chemotherapy Regimens App 20190321370 - Sorrentino; Jessica A. ; et al.	2019-10-24
Treatment of Rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitors Grant 10,413,547 - Strum , et al. Sept	2019-09-17
Anti-neoplastic Combinations And Dosing Regimens Using Cdk4/6 Inhibitor Compounds To Treat Rb-positive Tumors App 20190151311 - Strum; Jay Copeland ; et al.	2019-05-23
Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumors Grant 10,231,969 - Strum , et al.	2019-03-19
Treatment Of Rb-negative Tumors Using Topoisomerase Inhibitors In Combination With Cyclin Dependent Kinase 4/6 Inhibitors App 20190030034 - Strum; Jay Copeland ; et al.	2019-01-31
Treatment Of RB-Negative Tumors Using Topoisomerase Inhibitors In Combination With Cyclin Dependent Kinase 4/6 Inhibitors App 20170246171 - Strum; Jay Copeland ; et al.	2017-08-31
Anti-Neoplastic Combinations and Dosing Regimens using CDK4/6 Inhibitor Compounds to Treat RB-Positive Tumors App 20170182043 - Strum; Jay Copeland ; et al.	2017-06-29

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.